AzTrials
AzTrials

Chronic Kidney Disease(CKD)NCT06932042

PLADO for Conservative Management of CKD

A study testing PLADO and Standard-of-care diet in people with Chronic Kidney Disease(CKD) and Metabolic Acidosis, run by Lebanese American University at 1 site in Lebanon.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to learn if a plant-dominant low protein diet, referred to as PLADO diet, works to decrease metabolic acidosis, a major risk factor for chronic kidney disease (CKD) progression, in adults with CKD. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
PLADO and Standard-of-care diet
Could I receive a placebo?
No, everyone receives an active treatment
How many people
48 participants
Where
1 siteLebanon
Study dates
28 May 2024to 30 Jun 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients aged 18 years and above, having controlled glycemic and blood pressure parameters on treatment, with an established diagnosis of stages 3-5 CKD and an estimated GFR ≤59 ml/min/1.73 m2 stable for at least three months, and with a normal nutritional status as defined by the GLIM criteria, attending the CKD outpatient clinics at LAUMC-RH, willing to undergo the baseline screening and attend the monthly face-to-face visits at the outpatient department at LAUMC-RH.

Who cannot join

  • Patients with overt infection, persistent anorexia, vomiting, or diarrhea within the last month, presence of wasting diseases such as cancer, tuberculosis, liver failure, heart failure, and those with serum potassium >5.5 mEq/L during the past 6 months.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Rana Rizk, PhD, MS, MPH, LD contact

+9611786456 ext. 3741

rana.rizk01@lau.edu.lb

Lebanon1 site, 1 recruiting
  • Lebanese American University Medical Center- Rizk Hospital

    Beirut

    Joelle Abi Kharma, +9611200800 ext. 3806, joelle.abikharma@lau.edu.lb

    Recruiting

Other trials in Lebanon

About this study

Official title: Plant Dominant Low-protein Diet for Conservative Management of Chronic Kidney Disease: A Randomized Controlled Trial

The goal of this clinical trial is to learn if a plant-dominant low protein diet, referred to as PLADO diet, works to decrease metabolic acidosis, a major risk factor for chronic kidney disease (CKD) progression, in adults with CKD. It will also learn about the safety, viability, and economic attractiveness of this diet.

The main questions it aims to answer are:

Read more
  • Is the PLADO diet more effective in managing metabolic acidosis in comparison with the standard-of-care CKD diet in adults with CKD?
  • Is the PLADO diet safe, viable, and economically attractive adults with CKD?

Researchers will compare the PLADO diet to the standard-of-care CKD diet to see if the PLADO diet works better to decrease metabolic acidosis.

Participants will:

  • Receive nutrition education of the PLADO diet or the standard-of-care CKD diet via monthly sessions for 6 months.
  • Visit the clinic monthly for 6 months, then after 3 months for checkups and tests.
Being tested
PLADO, Standard-of-care diet
Keywords
Chronic kidney disease, metabolic acidosis, PLADO, Plant-dominant low protein diet, Nutrition education
Medical subject headings
Renal Insufficiency, Chronic, Acidosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PLADOOther

    Low protein plant-dominant diet (PLADO) of 0.6-0.8 g/kg/day of proteins with at least 50% plant-based sources, sodium of <4 g/day and <3 g/day in case of edema or hypertension, fibers of 25-30 g/day, and calories of 30-35 Kcal/kg/day provided in the form of individualized meal plans administered by a licensed/registered dietitian. The nutrition education intervention will be provided via a primary face-to-face education/counseling session of 45-60 minutes, followed by a monthly face-to-face follow-up session of 30-45 minutes for 6 months, and a face-to-face follow-up session of 30-45 minutes after 3 months. At each visit, participants will be screened according to the Transtheoretical behavior change model (TTM) using a TTM-based algorithm to determine their stage/readiness to adhere to PLADO and will receive stage-based education and counseling accordingly. Stage-based education will be divided into 1) Pre-contemplation and contemplation; 2) Preparation; and 3) Action and Maintenance

  • Standard-of-care dietOther

    Current standard-of-care diet composed of dietary protein, fluid, sodium potassium, and phosphorus restrictions provided via monthly face-to-face sessions of 30-45 minutes over a period of 6 months, and a follow-up session after 3 months provided by the same licensed/registered dietitian. Patients will be recruited to the control arm in the same period to avoid seasonal differences.

Study groups in NCT06932042
Study groupRoleWhat they receive
PLADOExperimentalNot described
Receives: Other: PLADO
Standard-of-care dietActive comparatorNot described
Receives: Other: Standard-of-care diet

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Metabolic acidosis assessed by PTCO2

    Measured: Baseline, Monthly for 6 months, Month 9

Secondary outcomes (34)
  1. Body weight

    Body weight measured using a balance beam scale Unit: kg

    Measured: Baseline, Months 3, 6, and 9

  2. %Weight Change

    %Weight Change (to the last measurement) Unit: %

    Measured: Months 3, 6, and 9

  3. Triceps Skinfold thickness

    Triceps Skinfold thickness measured using a measuring tape and a skinfold caliper Unit: mm

    Measured: Baseline, Months 3, 6, and 9

  4. Body Fat Percentage

    %Body Fat for edema-free patients assessed using Bioimpedance analysis (Maltron Bioscan) Unit: %

    Measured: Baseline, Months 3, 6, and 9

  5. Fat Free Mass Percentage

    %Fat Free Mass for edema-free patients assessed using Bioimpedance analysis (Maltron Bioscan) Unit: %

    Measured: Baseline, Months 3, 6, and 9

  6. Total Body Water Percentage

    %Total Body Water for edema-free patients assessed using Bioimpedance analysis (Maltron Bioscan) Unit: %

    Measured: Baseline, Months 3, 6, and 9

  7. Blood Urea Nitrogen (BUN)

    BUN assessed via blood test Unit: mg/dL

    Measured: Baseline, Monthly for 6 months, Month 9

  8. Estimated Glomerular Filtration Rate (eGFR)

    eGFR calculated using the Cockcroft-Gault equation = (((140 - age in years) x (weight in kg)) x 1.23) / (serum creatinine in micromol/l) Unit: mL/min/1.73m²

    Measured: Baseline, Monthly for 6 months, Month 9

  9. Serum Potassium (K)

    Serum K assessed via blood test Unit: mEq/L

    Measured: Baseline, Monthly for 6 months, Month 9

  10. Serum Phosphorus (P)

    Serum P assessed via blood test Unit: mg/dL

    Measured: Baseline, Monthly for 6 months, Month 9

  11. C-Reactive Protein (CRP)

    Serum CRP assessed via blood test Unit: mg/L

    Measured: Baseline, Months 3, 6, and 9

  12. Albumin

    Serum Albumin assessed via blood test Unit: g/dL

    Measured: Baseline, Months 3, 6, and 9

  13. Hemoglobin

    Serum Hemoglobin assessed via blood test Unit: g/dL

    Measured: Baseline, Months 3, 6, and 9

  14. Hematocrit

    Serum Hematocrit assessed via blood test Unit: %

    Measured: Baseline, Months 3, 6, and 9

  15. Mean Corpusculum Volume (MCV)

    Average size of red blood cells assessed via blood test Unit: Femtoliter (fL)

    Measured: Baseline, Months 3, 6, and 9

  16. Ferritin

    Serum Ferritin assessed via blood test Unit: ng/mL

    Measured: Baseline, Months 3, 6, and 9

  17. Glycated hemoglobin A1C

    Glycated hemoglobin (A1C) measured via blood test Unit: %

    Measured: Baseline, Months 3, 6, and 9

  18. Urinary microalbumin: creatinine ratio (UmACR)

    UmACR assessed via urine test Unit: mg/g creatinine

    Measured: Baseline, Months 3, 6, and 9

  19. Urinary potassium excretion

    Urinary potassium excretion (spot) measured via urine test Unit: meq/L

    Measured: Baseline, Months 3, 6, and 9

  20. Urinary phosphorus excretion

    Urinary phosphorus excretion (spot) measured via urine test Unit: mg/dL

    Measured: Baseline, Months 3, 6, and 9

  21. Global Leadership Initiative on Malnutrition (GLIM) criteria

    GLIM criteria for the diagnosis of malnutrition. A participant is identified as malnourished when at least one phenotypic and one etiologic criterion is met. Phenotypic criteria include unintentional weight loss (>5% within 6 months or >10% beyond 6 months), age-specific low Body Mass Index (< 20 kg/m2 for individuals < 70 years old and < 22 kg/m2 for individuals 70 years and older), and reduced muscle mass assessed using body composition parameters to detect muscle depletion. Etiologic criteria include reduced food intake or assimilation (defined as a reduction in energy intake > 50% of requirements for over one week or any reduction lasting more than 2 weeks) and the presence of acute disease or chronic diseases related inflammation.

    Score: one phenotypic criterion and one etiologic criterion, to diagnose malnutrition

    Measured: Baseline, Months 3, 6, and 9

  22. Total Caloric intake per kilogram body weight (Kcal/kg)

    The total caloric intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend). The estimated total caloric intake (Kcal) will then be divided by the body weight (kg) at the same time point of data collection.

    Unit: Kcal/kg

    Measured: Baseline, Months 3, 6, and 9

  23. Total dietary protein intake per kilogram body weight (g/kg)

    The total dietary protein intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend). The estimated total amount of dietary proteins in grams (g) will then be divided by the dry body weight (kg) at the same time point of data collection.

    Unit: g/kg

    Measured: Baseline, Months 3, 6, and 9

  24. Carbohydrate intake percentage (%)

    The total carbohydrate intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend). The estimated total amount of carbohydrate in grams (g) will then be multiplied by 4 Kcal to get the calories of carbohydrates. Afterwards, it will be divided by the total amount of calories consumed at the same time point of data collection to obtain the percentage of total intake.

    Unit: percentage (%)

    Measured: Baseline, Months 3, 6, and 9

  25. Total fat intake percentage (%)

    The total fat intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend). The estimated total amount of fat in grams (g) will then be multiplied by 9 Kcal to get the calories of fat. Afterwards, it will be divided by the total amount of calories consumed at the same time point of data collection to obtain the percentage of total intake.

    Unit: percentage (%)

    Measured: Baseline, Months 3, 6, and 9

  26. Trans fat intake percentage (%)

    The total trans-fat intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend). The estimated total amount of trans-fat in grams (g) will then be multiplied by 9 Kcal to get the calories of fat. Afterwards, it will be divided by the total amount of calories consumed at the same time point of data collection to obtain the percentage of total intake.

    Unit: percentage (%)

    Measured: Baseline, Months 3, 6, and 9

  27. Total potassium intake (g)

    The total potassium intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend) and reported in grams per day.

    Unit: g/d

    Measured: Baseline, Months 3, 6, and 9

  28. Total phosphorus intake (g)

    The total phosphorus intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend) and reported in grams per day.

    Unit: g/d

    Measured: Baseline, Months 3, 6, and 9

  29. Total sodium intake (g)

    The total sodium intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend) and reported in grams per day.

    Unit: g/d

    Measured: Baseline, Months 3, 6, and 9

  30. Nutrition focused physical examination (NFPE)

    The nutrition focused physical examination will be conducted by a licensed dietitian who will assess fat and muscle depletion, as well as the presence of edema.

    Measured: Baseline, Months 3, 6, and 9

  31. Muscle strength (kg)

    Muscle strength will be measured using a handgrip strength assessment with a calibrated hand dynamometer. Participants will be seated upright with their back supported, feet flat on the floor, and their elbow flexed at a 90-degree angle. The hand dynamometer will be adjusted to fit the participant's hand size who will be instructed to squeeze the dynamometer with maximum effort for 3-5 seconds. Three measurements will be taken for each hand, with a rest period of 30 to 60 seconds and the average of the three measurements will be recorded as the final handgrip strength.

    Unit: kg

    Measured: Baseline, Months 3, 6, and 9

  32. Gastrointestinal Symptoms

    Gastrointestinal symptoms will be assessed using the Birmingham IBS Symptom Questionnaire (B-IBS-Q), a validated tool for evaluating the frequency, severity, and impact of gastrointestinal symptoms. It is a self-administered questionnaire consisting of 11 items designed to assess the frequency of IBS-related symptoms, with each question having a standard response scale. Symptoms are measured based on a 6-point Likert scale (0-5) ranging from all of the time (5) to none (0) and converted to 100, with higher scores indicating more frequent IBS symptoms. The scale has 3 dimensions, including pain, constipation, and diarrhea.

    Measured: Baseline, Monthly for 6 months, Month 9

  33. Health-related Quality of Life

    Quality of life will be assessed using the EuroQOL-5D-5L (EQ-5D-5L), a widely validated and internationally recognized instrument for measuring health-related quality of life. The tool consists of two components: a descriptive system and a visual analog scale (VAS). The descriptive component includes five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a 5-level scale, ranging from no problems to extreme problems. Participants will select the most appropriate level that reflects their current health status for each dimension. The responses are then used to generate a health state profile, which can be converted into a single index score using country-specific value sets. In addition to the descriptive system, participants will rate their overall health status using a visual analog scale (VAS), ranging from 0 (worst imaginable health) to 100 (best imaginable health).

    Measured: Baseline, Months 3, 6, and 9

  34. Costs

    Costs relevant to direct medical costs, direct non-medical costs, and indirect costs assessed using a resource utilization questionnaire with the patients, and calculated following the identification, measurement, and valuation steps.

    Measured: Baseline, Months 3, 6, and 9

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Apr 2025
  2. Study start28 May 2024
  3. Primary completion30 Jun 2026 (estimated)
  4. Study completion30 Jun 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
48 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06932042
Sponsor's protocol ID
LAU.SAS.RR4.2/Feb/2024
Status last verified
Apr 2025
First submitted
1 Apr 2025
Last updated
17 Apr 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Kharma JA, Sultan R, Rizk R, Haroun D, Kilani H, Kalantar-Zadeh K, Gubbels J, Bessems K. Plant-dominant low-protein diet versus standard care in adults with chronic kidney disease stages 3-5: A randomized controlled trial protocol. Nutr Res. 2026 Jul;151:1-15. doi: 10.1016/j.nutres.2026.04.004. Epub 2026 Apr 22.

    PubMed 42155424

Questions about this trial

What is this clinical trial studying?

A study testing PLADO and Standard-of-care diet in people with Chronic Kidney Disease(CKD) and Metabolic Acidosis, run by Lebanese American University at 1 site in Lebanon.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 17 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Lebanon. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Rana Rizk, PhD, MS, MPH, LD (+9611786456 ext. 3741, rana.rizk01@lau.edu.lb), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Metabolic acidosis assessed by PTCO2 (time frame: Baseline, Monthly for 6 months, Month 9). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06932042, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in